At SDDS 2025, Bioptic revealed its next-gen platform that transforms how scientists go from targets to lead molecules using AI at scale. We’re thrilled to have presented Bioptic’s drug discovery platform at the 2025 Stanford Drug Discovery Symposium (SDDS), one of the world’s most respected forums for the future of pharmaceutical science. Our poster, titled “From Targets to Lead Molecules,” captured the attention of researchers, investors, and biotech innovators by demonstrating how AI can now fully power hit identification and lead optimization.
What We Showed?
An AI Engine for Every Step of Early Drug Discovery. Bioptic’s platform is built around three core models:
1. B1: Ligand-Based Hit ID
Using only a known active compound as input, our ultra-high-throughput engine screens 40B+ molecules in under 2.5 minutes — with 100% recall.
- It’s powered by a RoBERTa-based transformer trained on 160M+ SMILES, optimized using techniques from search engines and recommender systems.
- In a recent case study with Oncobox, we discovered VEGFR-3 inhibitors for solid tumors — with the top molecule showing IC50 = 420 nM and 4x faster hit-to-lead conversion.
2. B2: Sequence-Based Hit ID
Don’t have a known binder? No problem. Our Flamingo-inspired architecture can go directly from a protein sequence to hit compounds.
- Screens massive libraries in under a day
- Finds chemically diverse and novel molecules (< 0.4 Tanimoto similarity to known binders), making it ideal for IP generation and first-in-class drug programs
3. B3: ADME Predictions with Gemini
Early pharmacokinetics (PK) and safety profiles are built in. Our ADME module:
- Won the ASAP Antiviral ADMET challenge
- Uses few-shot learning to adapt to sparse or heterogeneous data
- Predicts key ADMET properties even in unexplored chemical space
Why It Matters
Bioptic’s platform brings the speed of search engines and the precision of modern AI to drug discovery. From novel scaffolds to selective inhibitors, from protein sequences to lead optimization — our system empowers scientists to design better drugs, faster.
SDDS 2025 reinforced the importance of AI in the scientific process. We were proud to be part of this year’s dialogue and to share our belief that the best drug discovery platforms must be data-native, target-agnostic, and radically fast.
Let’s Build the Future Together
If you missed us at Stanford, reach out or explore our platform. We’re always looking for great partners to accelerate therapeutic innovation..
